Showing 2 posts of 2 posts found.
The September edition of Pharmafocus is now available – click here to read online.
In a shock move, MSD Chairman and Chief Executive Officer Kenneth Frazier (pictured) has announced that he is to resign …
NHS England approves delayed-release treatment for rare kidney disease
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care
Five Facts about cardiovascular disease
Data integrity: the keystone for AI adoption, patient safety and organisational reputation